The patient access system isn't broken because people wanted it to fail. It's broken because it was built for an era where the phone and fax machine were the only universal interfaces, and business ...

A woman from the Wirral in the UK has become the first patient in the world to receive an experimental cancer vaccine ...

IGNYTE showed that patients with confirmed progression on an anti-PD-1-based regimen who received RP1 plus nivolumab had a 34% response rate, with a median duration of 24.8 months, and 15% of them ...

Hogan Lovells partner Alice Valder Curran returned to join pharmaphorum editor-in-chief Jonah Comstock to elucidate some of ...

The European Society for Medical Oncology (ESMO) Annual Congress has long been a bellwether for global oncology trends, and the 2025 meeting in Berlin was no exception. This year’s event showcased a ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another. The agreement with Gilead ...

Artificial intelligence (AI) is becoming embedded into the fabric of quality, compliance, and production systems and shaping how teams interact with software, how processes are managed, and how work ...

Armed with positive results in two phase 3 trials, Takeda intends to file for approval of its oral psoriasis therapy zasocitinib in the US and other countries next year, with Bristol Myers Squibb's ...

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...

Anti-OX40L antibody amlitelimab was discarded as a treatment for atopic dermatitis last week, and today – during its ...

The once-daily, oral TEC/JAK3 inhibitor has shown efficacy in active and stable nonsegmental vitiligo (NSV) – the most common form of the disease – in which the most common form of vitiligo, ...

FDA advisors have voted that Capricor Therapeutics has not provided strong evidence of efficacy for its cell therapy for ...